(FSTX) – Press Releases
-
Levicept Appoints Eliot Forster as CEO
-
invoX Pharma Completes Acquisition of F-star Therapeutics, Inc.
-
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
-
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
-
invoX Pharma and F-star Therapeutics issue Joint Statement
-
invoX Pharma and F-star Therapeutics issue Joint Statement
-
F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress
-
F-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 Congress
-
F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research
-
F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research
-
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
-
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
-
invoX Pharma Extends Tender Offer to Acquire F-star Therapeutics, Inc.
-
F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody
-
F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody
-
invoX Pharma Commences Tender Offer for F-star Therapeutics, Inc.
-
invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs
-
invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs
-
F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022
-
F-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022
-
F-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022
-
F-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022
-
F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update
-
F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
-
F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
-
F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022
-
F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022
-
F-star Therapeutics Appoints James Sandy as Chief Development Officer
-
F-star Therapeutics Appoints James Sandy as Chief Development Officer
-
F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3
-
F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3
-
F-star Therapeutics to Participate in Upcoming Investor Conferences
-
F-star Therapeutics to Participate in Upcoming Investor Conferences
-
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
-
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
-
F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021
-
F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021
-
F-star Therapeutics to Host Virtual R&D Day on December 6, 2021
-
F-star Therapeutics to Host Virtual R&D Day on December 6, 2021
-
F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
-
F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
-
Aerami Therapeutics Appoints Darlene Deptula-Hicks to its Board of Directors
-
F-star Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
F-star Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
F-star Therapeutics to Announce Third Quarter Results and Host Conference Call on November 10, 2021
-
F-star Therapeutics to Announce Third Quarter Results and Host Conference Call on November 10, 2021
-
F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics
-
F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics
Back to FSTX Stock Lookup
